MMinoryx Therapeutics — Series B · €21.3M
Fund+ led this €21.3M (~$24.8M) Series B, announced at BIOSPAIN 2018. Belgian co-investors SFPI-FPIM, S.R.I.W. and Sambrinvest joined, and all Series A investors took part again. The money expands indications for MIN-102 (leriglitazone) and moves a second orphan CNS indication into the clinic, taking total funding to about €50M.
The company
Investors 11
F
CCaixa Capital Risc (Criteria Bio Ventures)
www.criteriabioventures.com
Profile: Criteria Capital Risc
CChiesi Ventures
H
HealthEquity
IIdinvest Partners
www.eurazeo.com
Profile: Eurazeo
KKurma Partners
RRoche Venture Fund
SS.R.I.W.
SSambrinvest
SSFPI-FPIM
YYsios Capital
ysioscapital.com